omega-n-methylarginine has been researched along with dobutamine in 12 studies
| Studies (omega-n-methylarginine) | Trials (omega-n-methylarginine) | Recent Studies (post-2010) (omega-n-methylarginine) | Studies (dobutamine) | Trials (dobutamine) | Recent Studies (post-2010) (dobutamine) |
|---|---|---|---|---|---|
| 4,411 | 344 | 336 | 6,357 | 818 | 1,011 |
| Protein | Taxonomy | omega-n-methylarginine (IC50) | dobutamine (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 4.17 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 5.551 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 5.519 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.975 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 1.517 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.383 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 1.944 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 0.599 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 2.966 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.383 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.114 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.895 | |
| D(3) dopamine receptor | Homo sapiens (human) | 4.985 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.155 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 2.518 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balligand, JL; Colucci, WS; Hare, JM; Keaney, JF; Loscalzo, J; Smith, TW | 1 |
| Colucci, WS; Creager, MA; Hare, JM; Loh, E | 1 |
| Chelly, FD; Cromeens, DM; Griffith, OW; Kilbourn, RG | 1 |
| Chowienczyk, PJ; Dawes, M; Ritter, JM | 1 |
| Birder, LA; Finkel, MS; Kanai, AJ; Malinski, T; Mesaros, S; Oddis, CV | 1 |
| Colucci, WS; Creager, MA; Givertz, MM; Hare, JM | 1 |
| Hata, K; Kawai, H; Kijima, Y; Murata, T; Okubo, H; Shinke, T; Takaoka, H; Takeuchi, M; Yokoyama, M | 2 |
| Fetics, B; Hare, JM; Kass, DA; Maughan, WL; Pak, PH; Wittstein, IS | 1 |
| Frantz, S; Kelly, RA; Paulus, WJ | 1 |
| Bai, J; Bi, X; Chang, Q; Deng, Y; Li, C; Li, X; Liu, H; Liu, Y; Pan, M; Xiang, H; Yang, H | 1 |
| Mak, S; Newton, GE; Overgaard, CB | 1 |
3 trial(s) available for omega-n-methylarginine and dobutamine
| Article | Year |
|---|---|
Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Arginine; Dobutamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Forearm; Humans; Male; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Vasodilation; Vasodilator Agents | 1997 |
Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to beta-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy.
Topics: Adrenergic beta-Agonists; Adult; Blood Pressure; Cardiac Volume; Cardiomyopathy, Dilated; Diastole; Dobutamine; Energy Metabolism; Enzyme Inhibitors; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Myocardial Contraction; Myocardium; Nitric Oxide; omega-N-Methylarginine; Oxygen Consumption; Pulmonary Wedge Pressure; Systole | 2000 |
Effect of vitamin C and L-NMMA on the inotropic response to dobutamine in patients with heart failure.
Topics: Ascorbic Acid; Blood Pressure; Cardiotonic Agents; Dobutamine; Drug Combinations; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Myocardial Contraction; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Treatment Outcome; Ventricular Dysfunction, Left | 2005 |
9 other study(ies) available for omega-n-methylarginine and dobutamine
| Article | Year |
|---|---|
Role of nitric oxide in parasympathetic modulation of beta-adrenergic myocardial contractility in normal dogs.
Topics: Amino Acid Oxidoreductases; Animals; Arginine; Cyclic AMP; Dobutamine; Dogs; Electric Stimulation; Heart; Heart Rate; Muscarinic Antagonists; Myocardial Contraction; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Receptors, Adrenergic, beta; Vagus Nerve | 1995 |
Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction.
Topics: Adrenergic beta-Agonists; Arginine; Dobutamine; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myocardial Contraction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Stimulation, Chemical; Ventricular Dysfunction, Left | 1995 |
NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs.
Topics: Animals; Arginine; Cardiovascular System; Dobutamine; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Male; Nitric Oxide; omega-N-Methylarginine; Prospective Studies; Random Allocation; Shock, Septic; Time Factors | 1994 |
Beta-adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes.
Topics: 1-Methyl-3-isobutylxanthine; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Aging; Animals; Animals, Newborn; Bucladesine; Calcimycin; Cells, Cultured; Dobutamine; Enzyme Induction; Guanosine Diphosphate; Heart; Interleukin-1; Isoproterenol; Myocardial Contraction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Norepinephrine; omega-N-Methylarginine; Rats; Receptors, Adrenergic, beta; Terbutaline; Thionucleotides; Trifluoperazine | 1997 |
Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness.
Topics: Acetylcholine; Adrenergic beta-Agonists; Cardiomyopathy, Dilated; Dobutamine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Nitric Oxide Synthase; omega-N-Methylarginine; Ventricular Dysfunction, Left | 1998 |
[Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to beta-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy].
Topics: Cardiomyopathy, Dilated; Dobutamine; Enzyme Inhibitors; Humans; Middle Aged; Myocardial Contraction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Oxygen Consumption; Receptors, Adrenergic, beta | 2001 |
Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cardiomyopathy, Dilated; Compliance; Depression, Chemical; Diastole; Dobutamine; Enalaprilat; Enzyme Inhibitors; Female; Heart; Hemodynamics; Humans; Losartan; Male; Middle Aged; Myocardial Contraction; Myocardium; Nitric Oxide; omega-N-Methylarginine; Ventricular Dysfunction, Left | 2001 |
Nitric oxide and cardiac contractility in human heart failure: time for reappraisal.
Topics: Adrenergic beta-Agonists; Animals; Blood Pressure; Cyclic AMP; Cyclic GMP; Dobutamine; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Heart Failure; Humans; Isoenzymes; Myocardial Contraction; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; omega-N-Methylarginine; Rats; Substance P; Ventricular Function, Left | 2001 |
Nitric oxide formation contributes to beta-adrenergic dilation of epicardial coronary arteries in response to intravenous administration of dobutamine in dogs.
Topics: Adrenergic beta-Agonists; Animals; Coronary Vessels; Dobutamine; Dogs; Echocardiography; Female; Male; Nitric Oxide; omega-N-Methylarginine; Receptors, Adrenergic, beta; Vasodilation | 2004 |